The FDA recently approved the first generic version of Tamiflu (oseltamivir phosphate) for the treatment of influenza A and B in patients two weeks of age and older. The drug is also approved for the prevention of the flu in patients one year of age and older.
Tamiflu, manufactured by Roche, was approved in 1999. The FDA noted that the most common side effects reported by people using oseltamivir phosphate in clinical trials included nausea and vomiting.
It also emphasized that oseltamivir phosphate does not take the place of receiving a flu vaccination.
“The FDA does not know if oseltamivir phosphate is effective in people who start treatment after two days of developing symptoms, or have weakened immune systems,” the agency said.
More information is available at the FDA website.
